Last update Nov. 5, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Fenspiride Hydrochloride is also known as
Fenspiride Hydrochloride in other languages or writings:
Fenspiride Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Fenspiride Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 90 | % |
Molecular weight | 297 | daltons |
VD | 3.0 | l/Kg |
pKa | 12.29 | - |
Tmax | 2.3 -6 | hours |
T½ | 12 - 16 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Oxazolidonic compound with antihistaminic, anti-inflammatory and bronchodilator actions not well studied. Indicated in the symptomatic treatment of cough and expectoration of bronchial and lung inflammatory diseases. (Medana 2015, Quartulli 1998)
At the date of last update we did not find published data on its excretion in breast milk.
In the absence of knowing the percentage of plasma protein binding, its known pharmacokinetic data (Medana 2015, Montes 1993): low molecular weight, half-life of more than 12 hours, make it likely to pass into milk in an amount that could be significant and that could reach the infant's plasma (high oral bioavailability).
Its possible adverse effects are mild and not very frequent. (Medana 2015)
Authorized pediatric use from two years of age. Product little studied in humans, with very few bibliographic references and marketed in very few countries.
Until more published data on this drug in relation to breastfeeding are known, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
In 2019, the National Agency (France) for Drug Safety suspended the marketing authorization of Fenspiride because of the risk of QT prolongation. (ANSM 2019)